Life Sciences

  • Share

Life Sciences transactions advisory services

EY - Find out how they can support the capital agenda of your portfolio company
 

Executing on the investment strategy

In today's market, the life sciences companies that can define a clear strategy, deploy capital effectively against that strategy and continue to innovate will win. Having the right advisors who understand your investment strategy, know your team, have the relevant transaction skills and industry knowledge and are ready when you are can help make the difference.EY - The Life Sciences Capital Agenda

How we can help

The Life Sciences Capital Agenda framework helps connect your overall capital strategy to our services as you focus on the cornerstones of preserving, optimizing, investing and raising capital. It also helps you consider capital options throughout the economic cycle. Choosing the right options will help you make the decisions needed to succeed in today's environment where volatility is the only constant.

Our transaction professionals understand and can help you execute the increasingly innovative transactions that are redefining the life sciences industry.

EY in the media

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY - Working capital report - Cash on prescription

Working capital report - Cash on prescription

Pharma saw improved working capital performance in 2013, but progress has not been sufficient to reverse deterioration of previous years. Our report explores.

EY - Pharma's $100 billion growth gap

Pharma's $100 billion growth gap

As big pharma faces a widening growth gap, our Firepower Index highlights industry's capacity for deals in 2013 and beyond.